Special Issue "Application of Next-Generation Sequencing in Cancers"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 July 2019
Dr. Vivek Subbiah
Department of Investigational Cancer Therapeutics (A Phase 1 Program), Division of Cancer Medicine, The University of MD Anderson Cancer Center, Houston, TX 77030, USA
Website | E-Mail
Interests: adolescent and young adult oncology; clinical trials with molecularly targeted agents; dramatic responses in cancer patients; N–of-ONE studies; deep sequencing; morphoproteomics; next generation sequencing; Phase 1 trials—drug development (targeted therapy, radiopharmaceutical therapy, and immunotherapy); Basket trials; Rare Oncology histology agnostic trials
Cancer is a genetic disease. With the advent of precision medicine, there has been an explosive growth in the availability of potent genomically and immunologically targeted agents. Consequently, comprehensive analysis of every cancer is quickly becoming essential. The advent of clinical next generation sequencing technologies has fueled growth in precision oncology. Genomic testing permits the interrogation of the inside of the cell and the definition of a tumor’s precise coding sequence. Technology is evolving at a breathtaking pace. Sequencing a human genome was first performed for about $3 billion dollars in 2003, yet currently costs about $1000. Because of this rapid evolution, defining the best technology for patients is a moving target. Multiplex, pan-cancer, next-generation sequencing (NGS) has tremendous advantages over the current 1-drug, 1-gene test model: tissue is not wasted with multiple individual tests, a comprehensive genomic portfolio is created, and multiplex testing costs are lower than for numerous individual tests. However, the optimal panels are quickly evolving and include assessment of circulating tumor DNA from blood samples (liquid biopsies). Real-time ongoing reevaluation is needed. In this series, we invite authors to submit papers on:
- Next generation sequencing in cancers;
- Exceptional responders to precision cancer therapy;
- Next generation sequencing for immunotherapy and immuno-oncology;
- Broad NGS application in cancers
- Basket trials
- Genomic and Proteomic data from Public databases like TCGA.
Dr. Vivek Subbiah
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.